Melanoma occurring during treatment with fingolimod for multiple sclerosis: A case report

Archives of Dermatology

Volumn 147, Issue 8, 2011, Pages 991-992

  Baumann Conzett, Katrin ^a   Kolm, Isabel ^a   Jelcic, Ilijas ^b   Kamarachev, Jivko ^a   Dummer, Reinhard ^a   Braun, Ralph ^a   French, Lars E ^a   Linnebank, Michael ^b   Hofbauer, Günther F L ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD;

ADULT; CASE REPORT; CUTANEOUS MELANOMA; DRUG WITHDRAWAL; EPILUMINESCENCE MICROSCOPY; FEMALE; HUMAN; HUMAN TISSUE; LETTER; MELANOMA; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SKIN EXAMINATION;

ADULT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MELANOMA; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; SKIN NEOPLASMS; SPHINGOSINE;

EID: 80051688285     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.212     Document Type: Letter

References (5)

1. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004; 427(6972):355-360. (Pubitemid 38133663)
2. Cohen JA, Barkhof F, Comi G, et al TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-415.
3. Kappos L, Radue EW, O'Connor P, et al FREEDOMS Study Group. A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
4. Massberg S, von Andrian UH. Fingolimod and sphingosine-1-phosphate: modifiers of lymphocyte migration. N Engl J Med. 2006;355(11):1088-1091. (Pubitemid 44394915)
5. LaMontagne K, Littlewood-Evans A, Schnell C, et al. Antagonism of sphingosine- 1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res. 2006;66(1):221-231. (Pubitemid 43166028)